News - RNA / BOC Sciences

News

Vutrisiran, The World's Fourth RNAi Therapy, Is About to Submit A Marketing Application

From COVID-19 Vaccines to Anti-Cancer Drugs, What Is the Prospect of mRNA Therapy?

Alnylam's third RNAi therapy Lumasiran was approved by the European Union for the treatment of primary hyperoxaluria type 1 (PH1)

Breaking news: RNAi can significantly inhibit hepatitis B and is expected to become a new treatment for HBV

Competing for the last mile of vaccine research and development, mRNA vaccines become a hot spot for competition

Will the mRNA vaccine become the "savior" of COVID-19?

mRNA-1647，the first infectious disease mRNA vaccine to enter the second phase of research

FDA approves first RNAi treatment for inherited rare diseases

bioRxiv.: Scientists Find siRNA drugs that may inhibit SARS-CoV-2

Cell Immunity: SARS-CoV-2 vaccines status

Onpattro, The First FDA-approved RNAi Drug

SARS-CoV-2 is undergoing mutations. Does the vaccine still work?

* Only for research. Not suitable for any diagnostic or therapeutic use.

CONTACT US

- Call us at:
Email:
Fax:

USA

Email:

Europe

Email:
Germany - UK